基于结核分枝杆菌免疫反应性调查指导的主动病例发现:马拉维布兰太尔的健康影响与成本数学建模研究
该数学建模研究比较了马拉维布兰太尔33个城市社区中被动病例发现、非靶向主动病例发现和基于5岁以下儿童结核分枝杆菌免疫反应性调查估算的年度结核感染风险指导的靶向主动病例发现的健康影响与成本。结果显示靶向主动病例发现覆盖半数人群可识别80%的结核患者,且每避免一个伤残调整生命年的成本低于非靶向策略,但成本效果比仍超过马拉维现有阈值。
要点
- 靶向主动病例发现覆盖半数人群可识别80%的结核患者。
- 靶向策略每避免一个DALY成本为400美元,低于非靶向的700美元。
- 成本效果比在更高结核患病率或更大传播减少假设下改善。
核心结论
- 利用结核分枝杆菌免疫反应性调查数据靶向主动病例发现可比非靶向方法显著改善健康影响和成本效果。
- 但需要低成本的数据收集方法才能更广泛地采用。
研究设计与样本
- 数学建模研究,使用参数化的本地数据,比较三种病例发现策略。
- 研究地点为马拉维布兰太尔33个城市社区,使用马尔可夫微观模拟模型估算健康结局和成本。
- 成本从卫生系统和社会视角评估,并针对ARTI与真实结核患病率关系的不同假设进行计算。
主要发现
- 与非靶向主动病例发现相比,靶向主动病例发现覆盖半数研究人群估计可识别80%的结核患者。
- 靶向主动病例发现每避免一个DALY的成本为400美元(95% CrI [20, 1000]),低于非靶向主动病例发现的700美元(95% CrI [100, 1500])。
- 与仅被动病例发现相比,非靶向主动病例发现估计可使结核病患者的预期寿命提高3.3年(95% CrI [1.7, 5.4]),但成本高昂。
- 主要分析中,这些成本效果比超过了马拉维现有的成本效果阈值。
临床怎么用
- 可考虑利用结核分枝杆菌免疫反应性调查数据指导靶向主动病例发现以优化资源配置。
- 在决定实施靶向主动病例发现时需结合本地结核患病率和成本效果阈值进行评估。
局限性
- 研究基于数学建模,存在若干局限性。
- ARTI与结核患病率之间的关系不确定,相关假设影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active case finding (ACF) for tuberculosis (TB) can reduce transmission, yet efficient targeting requires high-quality surveillance data. We investigated the potential costs and impact of targeted ACF, guided by local estimates of the annual risk of TB infection (ARTI) derived from Mycobacterium tuberculosis (Mtb) immunoreactivity survey data in children aged <5 years. METHODS AND FINDINGS: Using mathematical models parameterized with local data, we compared three case-finding approaches across 33 urban neighborhoods in Blantyre, Malawi: passive case finding (PCF) only; PCF with untargeted ACF; and PCF with ARTI-guided targeted ACF. Health outcomes (life expectancy, disability-adjusted life years [DALYs]) and costs were estimated using a Markov microsimulation model. Costs were assessed from health system and societal perspectives. Results were calculated for different assumptions about the relationship between ARTI and true TB prevalence. Compared to PCF-only, untargeted ACF was estimated to improve life expectancy by 3.3 years (95% credible interval (CrI) [1.7, 5.4]) for individuals with TB disease, but at high cost. Targeted ACF covering half of the study population was estimated to identify 80% of all individuals with TB and achieved a lower cost per DALY averted (US$400, 95% CrI [20,1,000]) than untargeted ACF (US$700, 95% CrI [100, 1,500]). In the main analysis, these cost-effectiveness ratios exceeded available cost-effectiveness thresholds for Malawi, although cost-effectiveness improved under assumptions of higher TB prevalence or greater transmission reduction. The findings are based on mathematical modeling and are subject to several limitations, including assumptions regarding the relationship between ARTI and TB prevalence, which remains uncertain. CONCLUSIONS: Targeting ACF using Mtb immunoreactivity survey data could substantially improve health impact and cost-effectiveness compared to untargeted approaches. However, low-cost approaches for collecting these data are needed for wider adoption.
引用
- Kim S, Can MH, Rickman HM, et al. Potential health impacts and costs of active case finding guided by Mycobacterium tuberculosis immunoreactivity survey results in Blantyre, Malawi: A mathematical modeling study. PLoS Med. 2026. PMID: 42842627. doi:10.1371/journal.pmed.1005272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。